DK1382604T3 - Quinolinderivater med en azolylgruppe og quinazolinderivater - Google Patents

Quinolinderivater med en azolylgruppe og quinazolinderivater

Info

Publication number: DK1382604T3
Authority: DK; Denmark
Prior art keywords: derivatives; represent; azolyl group; quinazoline; quinoline
Prior art date: 2001-04-27

Application number

DK02724651T

Other languages

Danish (da)

English (en)

Inventor

Kazuo Kubo

Teruyuki Sakai

Rika Nagao

Yasunari Fujiwara

Toshiyuki Isoe

Kazumasa Hasegawa

Original Assignee

Kirin Brewery

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-27

Filing date

2002-04-26

Publication date

2006-04-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18980738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1382604(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-26 Application filed by Kirin Brewery filed Critical Kirin Brewery

2006-04-18 Application granted granted Critical

2006-04-18 Publication of DK1382604T3 publication Critical patent/DK1382604T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Luminescent Compositions (AREA)
Adhesives Or Adhesive Processes (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Polymerization Catalysts (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

DK02724651T 2001-04-27 2002-04-26 Quinolinderivater med en azolylgruppe og quinazolinderivater DK1382604T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2001132775		2001-04-27

Publications (1)

Publication Number	Publication Date
DK1382604T3 true DK1382604T3 (da)	2006-04-18

Family

ID=18980738

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02724651T DK1382604T3 (da)	2001-04-27	2002-04-26	Quinolinderivater med en azolylgruppe og quinazolinderivater

Country Status (24)

Country	Link
US (2)	US6821987B2 (es)
EP (2)	EP1382604B1 (es)
JP (1)	JP2010077131A (es)
KR (1)	KR100879669B1 (es)
CN (1)	CN1273466C (es)
AT (1)	ATE396988T1 (es)
AU (1)	AU2002255284B2 (es)
BE (1)	BE2018C008I2 (es)
BR (1)	BRPI0209216B8 (es)
CA (1)	CA2445333C (es)
DE (2)	DE60208364T2 (es)
DK (1)	DK1382604T3 (es)
ES (1)	ES2256466T3 (es)
FR (1)	FR18C1006I2 (es)
IL (1)	IL158459A0 (es)
MX (1)	MXPA03009662A (es)
NL (1)	NL300927I9 (es)
NO (2)	NO326325B1 (es)
NZ (1)	NZ529046A (es)
PL (1)	PL209822B1 (es)
RU (1)	RU2283841C2 (es)
TW (1)	TWI324154B (es)
WO (1)	WO2002088110A1 (es)
ZA (1)	ZA200307861B (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL144461A0 (en) *	1999-01-22	2002-05-23	Kirin Brewery	Quinoline and quinazoline derivatives and pharmaceutical compositions containing them
US7135466B2 (en) *	1999-12-24	2006-11-14	Kirin Beer Kabushiki Kaisha	Quinoline and quinazoline derivatives and drugs containing the same
US7879840B2 (en) *	2005-08-25	2011-02-01	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040048780A1 (en) *	2000-05-10	2004-03-11	The Trustees Of Columbia University In The City Of New York	Method for treating and preventing cardiac arrhythmia
US20060293266A1 (en) *	2000-05-10	2006-12-28	The Trustees Of Columbia	Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7718644B2 (en) *	2004-01-22	2010-05-18	The Trustees Of Columbia University In The City Of New York	Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en)	2000-05-10	2011-09-20	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en)	2000-05-10	2008-07-01	The Trustees Of Columbia University In The City Of New York	Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040229781A1 (en) *	2000-05-10	2004-11-18	Marks Andrew Robert	Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US6489125B1 (en) *	2000-05-10	2002-12-03	The Trustees Of Columbia University In The City Of New York	Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
EP1415987B1 (en) *	2000-10-20	2007-02-28	Eisai R&D Management Co., Ltd.	Nitrogenous aromatic ring compounds as anti cancer agents
ATE396988T1 (de)	2001-04-27	2008-06-15	Kirin Pharma Kk	Chinolin- und chianzolinderivate zur behandlung von tumoren
US7425564B2 (en) *	2001-06-22	2008-09-16	Kirin Beer Kabushiki Kaisha	Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same
WO2003033472A1 (en) *	2001-10-17	2003-04-24	Kirin Beer Kabushiki Kaisha	Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
WO2003093238A1 (en) *	2002-05-01	2003-11-13	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
EP1521747B1 (en)	2002-07-15	2018-09-05	Symphony Evolution, Inc.	Receptor-type kinase modulators and methods of use
US7166722B2 (en)	2002-10-21	2007-01-23	Kirin Beer Kabushiki Kaisha	N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form
AU2003280599A1 (en) *	2002-10-29	2004-05-25	Kirin Beer Kabushiki Kaisha	QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
US7544678B2 (en) *	2002-11-05	2009-06-09	The Trustees Of Columbia University In The City Of New York	Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
WO2004060373A1 (ja) *	2002-12-27	2004-07-22	Santen Pharmaceutical Co., Ltd.	滲出型加齢黄斑変性治療剤
AU2004220548A1 (en)	2003-03-07	2004-09-23	The Trustees Of Columbia University, In The City Of New York	Type 1 ryanodine receptor-based methods
EP1604665B1 (en) *	2003-03-10	2011-05-11	Eisai R&D Management Co., Ltd.	C-kit kinase inhibitor
SI2392564T1 (sl) *	2003-09-26	2014-02-28	Exelixis, Inc.	c-Met modulatorji in postopki uporabe
EP1683785B1 (en)	2003-11-11	2013-10-16	Eisai R&D Management Co., Ltd.	Urea derivative and process for producing the same
JP2007512255A (ja) *	2003-11-13	2007-05-17	アンビットバイオサイエンシスコーポレーション	キナーゼ調節因子としての尿素誘導体
US8710045B2 (en) *	2004-01-22	2014-04-29	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the ryanodine receptors
EP1711495A2 (en) *	2004-01-23	2006-10-18	Amgen Inc.	Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
TW200530236A (en)	2004-02-23	2005-09-16	Chugai Pharmaceutical Co Ltd	Heteroaryl phenylurea
DE602005013990D1 (de)	2004-09-17	2009-05-28	Eisai R&D Man Co Ltd	Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
EP1874759A4 (en) *	2005-04-06	2009-07-15	Exelixis Inc	C-MET MODULATORS MODULATORS AND METHODS OF USE
TW200740820A (en) *	2005-07-05	2007-11-01	Takeda Pharmaceuticals Co	Fused heterocyclic derivatives and use thereof
US20100105031A1 (en) *	2005-08-01	2010-04-29	Esai R & D Management Co., Ltd.	Method for prediction of the efficacy of vascularization inhibitor
JP4989476B2 (ja)	2005-08-02	2012-08-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	血管新生阻害物質の効果を検定する方法
US7704990B2 (en) *	2005-08-25	2010-04-27	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007026864A1 (ja) *	2005-09-01	2007-03-08	Eisai R & D Management Co., Ltd.	崩壊性の改善された医薬組成物の製造方法
US20090053236A1 (en)	2005-11-07	2009-02-26	Eisai R & D Management Co., Ltd.	USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
WO2007061130A1 (ja) *	2005-11-22	2007-05-31	Eisai R & D Management Co., Ltd.	多発性骨髄腫に対する抗腫瘍剤
AU2007252506C1 (en) *	2006-05-18	2012-07-19	Eisai R & D Management Co., Ltd.	Antitumor agent for thyroid cancer
WO2008001956A1 (en) *	2006-06-29	2008-01-03	Eisai R & D Management Co., Ltd.	Therapeutic agent for liver fibrosis
EP2065372B1 (en)	2006-08-28	2012-11-28	Eisai R&D Management Co., Ltd.	Antitumor agent for undifferentiated gastric cancer
CA2676796C (en)	2007-01-29	2016-02-23	Eisai R & D Management Co., Ltd.	Composition for treatment of undifferentiated gastric cancer
ES2635131T3 (es)	2007-08-29	2017-10-02	Methylgene Inc.	Inhibidores de la actividad de la proteína tirosina cinasa
KR101513326B1 (ko)	2007-11-09	2015-04-17	에자이 알앤드디 매니지먼트 가부시키가이샤	혈관 신생 저해 물질과 항종양성 백금 착물의 병용
EP2248804A4 (en) *	2008-01-29	2014-09-10	Eisai R&D Man Co Ltd	COMBINED USE OF AN ANGIOGENESIS INHIBITOR AND A TAXANE
PT2947072T (pt)	2008-03-17	2016-12-06	Ambit Biosciences Corp	1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas
MX2011007620A (es)	2009-01-16	2011-11-04	Exelixis Inc	Sal de malato de n(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n '-(4-fluorofenil) ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer.
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2010285740C1 (en)	2009-08-19	2016-03-17	Eisai R&D Management Co., Ltd.	Quinoline derivative-containing pharmaceutical composition
US7998973B2 (en) *	2009-11-13	2011-08-16	Aveo Pharmaceuticals, Inc.	Tivozanib and temsirolimus in combination
MX2012014776A (es)	2010-06-25	2013-01-29	Eisai R&D Man Co Ltd	Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
EP2594566A4 (en) *	2010-07-16	2014-10-01	Kyowa Hakko Kirin Co Ltd	AROMATIC HETEROCYCLIC NITROGEN CYCLE DERIVATIVE
EA022873B1 (ru)	2010-10-27	2016-03-31	Новартис Аг	Применение ингибитора vegf-r2 для лечения офтальмологического сосудистого заболевания
BR112013021941B1 (pt)	2011-04-18	2022-11-16	Eisai R & D Management Co., Ltd	Agente terapêutico para tumor
EP3444363B1 (en)	2011-06-03	2020-11-25	Eisai R&D Management Co., Ltd.	Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102532116B (zh) *	2011-08-09	2015-01-21	武汉迈德森医药科技有限公司	抗肿瘤靶向治疗药物tivozanib的合成方法
CN102408411B (zh) *	2011-09-19	2014-10-22	北京康辰药业股份有限公司	一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN102408418A (zh) *	2011-10-21	2012-04-11	武汉迈德森医药科技有限公司	Tivozanib酸性盐及其制备方法和晶型
EP2626073A1 (en)	2012-02-13	2013-08-14	Harmonic Pharma	Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (PDE4)
WO2014098176A1 (ja)	2012-12-21	2014-06-26	エーザイ・アール・アンド・ディー・マネジメント株式会社	キノリン誘導体のアモルファス及びその製造方法
CN105264380B (zh)	2013-05-14	2017-09-05	卫材R&D管理有限公司	用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
MX2016000364A (es)	2013-07-12	2016-05-09	Ophthotech Corp	Metodos para tratar o prevenir afecciones oftalmologicas.
MX394386B (es)	2014-08-28	2025-03-24	Eisai R&D Man Co Ltd	Derivado de quinolina muy puro y metodo para su produccion.
JP6852848B2 (ja)	2015-01-13	2021-03-31	国立大学法人京都大学	筋萎縮性側索硬化症の予防及び／又は治療剤
MX385403B (es)	2015-02-25	2025-03-18	Eisai R&D Man Co Ltd	Método para suprimir el amargor de un derivado de quinoleína.
KR20250020678A (ko)	2015-03-04	2025-02-11	머크 샤프 앤드 돔 엘엘씨	암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
SG11201710198YA (en)	2015-06-16	2018-01-30	Eisai R&D Man Co Ltd	Anticancer agent
WO2017030161A1 (ja)	2015-08-20	2017-02-23	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療剤
KR20180086187A (ko)	2015-10-05	2018-07-30	더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕	자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
WO2018028591A1 (zh)	2016-08-09	2018-02-15	殷建明	一种喹啉衍生物及其用途
CN106478621B (zh) *	2016-09-30	2018-12-25	遵义医学院	喹啉或喹唑啉类衍生物、制备方法及其应用
WO2018102455A1 (en)	2016-12-01	2018-06-07	Ignyta, Inc.	Methods for the treatment of cancer
CN108341813B (zh) *	2017-01-24	2020-11-17	四川大学	取代的1-(异恶唑-3-基)-3-(3-氟-4-苯基)脲衍生物及其制备方法和用途
EP3581183B1 (en)	2017-02-08	2023-11-29	Eisai R&D Management Co., Ltd.	Tumor-treating pharmaceutical composition
CN108530455B (zh) *	2017-03-01	2021-01-12	北京赛特明强医药科技有限公司	脲取代的芳环连二噁烷并喹唑啉类化合物或药用盐或水合物及作为酪氨酸激酶抑制剂的应用
US11053223B2 (en)	2017-04-27	2021-07-06	Astrazeneca Ab	Phenoxyquinazoline compounds and their use in treating cancer
KR102603153B1 (ko)	2017-04-27	2023-11-15	아스트라제네카 아베	C5-아닐리노퀴나졸린 화합물 및 암의 치료에서의 이의 용도
CN110831597A (zh)	2017-05-16	2020-02-21	卫材R&D管理有限公司	肝细胞癌的治疗
CN109553612B (zh) *	2017-09-26	2021-09-03	广西梧州制药（集团）股份有限公司	一种吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
CA3090829C (en)	2018-02-11	2023-05-09	Beijing Scitech-Mq Pharmaceuticals Limited	Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof
EP3876934A4 (en)	2018-11-05	2022-08-03	Aveo Pharmaceuticals, Inc.	Use of tivozanib to treat subjects with refractory cancer
SG11202106635WA (en)	2018-12-21	2021-07-29	Daiichi Sankyo Co Ltd	Combination of antibody-drug conjugate and kinase inhibitor
EP4430047A1 (en)	2021-11-08	2024-09-18	Progentos Therapeutics, Inc.	Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023096651A1 (en)	2021-11-26	2023-06-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods for treating bile duct cancers with tivozanib
EP4531927A1 (en)	2022-05-24	2025-04-09	Daiichi Sankyo Company, Limited	Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2024095127A1 (en)	2022-10-31	2024-05-10	Pliva Hrvatska D.O.O.	Solid state forms of tivozanib and process for preparation thereof
WO2024110606A1 (en) *	2022-11-25	2024-05-30	Synthon B.V.	A process for preparation of cabozantinib or tivozanib
WO2025120654A1 (en) *	2023-12-05	2025-06-12	Natco Pharma Limited	An improved process for the preparation of tivozanib hydrochloride hydrate
WO2025253311A1 (en)	2024-06-04	2025-12-11	Hetero Labs Limited	1,2-dicarboxamide compounds as kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2728878B2 (ja)	1987-12-15	1998-03-18	大倉工業株式会社	中空押出成形板
GB9000644D0 (en) *	1990-01-11	1990-03-14	Erba Carlo Spa	New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
US6143764A (en) *	1995-11-07	2000-11-07	Kirin Beer Kabushiki Kaisha	Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
JP4194678B2 (ja)	1997-11-28	2008-12-10	キリンファーマ株式会社	キノリン誘導体およびそれを含む医薬組成物
WO1999032111A1 (en)	1997-12-22	1999-07-01	Bayer Corporation	INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
CA2315717C (en)	1997-12-22	2011-02-01	Bayer Corporation	Inhibition of raf kinase using substituted heterocyclic ureas
IL144461A0 (en)	1999-01-22	2002-05-23	Kirin Brewery	Quinoline and quinazoline derivatives and pharmaceutical compositions containing them
US7135466B2 (en)	1999-12-24	2006-11-14	Kirin Beer Kabushiki Kaisha	Quinoline and quinazoline derivatives and drugs containing the same
JP2002030083A (ja)	2000-07-18	2002-01-29	Kirin Brewery Co Ltd	Ｎ−（２−クロロ−４−｛［６−メトキシ−７−（３−ピリジルメトキシ）−４−キノリル］オキシ｝フェニル）−ｎ’−プロピルウレアの二塩酸塩
EP1415987B1 (en) *	2000-10-20	2007-02-28	Eisai R&D Management Co., Ltd.	Nitrogenous aromatic ring compounds as anti cancer agents
ATE396988T1 (de)	2001-04-27	2008-06-15	Kirin Pharma Kk	Chinolin- und chianzolinderivate zur behandlung von tumoren

2002
- 2002-04-26 AT AT05028370T patent/ATE396988T1/de not_active IP Right Cessation
- 2002-04-26 US US10/132,473 patent/US6821987B2/en not_active Expired - Lifetime
- 2002-04-26 EP EP02724651A patent/EP1382604B1/en not_active Expired - Lifetime
- 2002-04-26 ES ES02724651T patent/ES2256466T3/es not_active Expired - Lifetime
- 2002-04-26 CA CA2445333A patent/CA2445333C/en not_active Expired - Lifetime
- 2002-04-26 BR BRPI0209216A patent/BRPI0209216B8/pt not_active IP Right Cessation
- 2002-04-26 AU AU2002255284A patent/AU2002255284B2/en not_active Expired
- 2002-04-26 NZ NZ529046A patent/NZ529046A/en not_active IP Right Cessation
- 2002-04-26 DE DE60208364T patent/DE60208364T2/de not_active Expired - Lifetime
- 2002-04-26 DK DK02724651T patent/DK1382604T3/da active
- 2002-04-26 IL IL15845902A patent/IL158459A0/xx active IP Right Grant
- 2002-04-26 DE DE60226912T patent/DE60226912D1/de not_active Expired - Lifetime
- 2002-04-26 RU RU2003134376/04A patent/RU2283841C2/ru active
- 2002-04-26 KR KR1020037013939A patent/KR100879669B1/ko not_active Expired - Lifetime
- 2002-04-26 EP EP05028370A patent/EP1652847B1/en not_active Expired - Lifetime
- 2002-04-26 MX MXPA03009662A patent/MXPA03009662A/es active IP Right Grant
- 2002-04-26 PL PL367105A patent/PL209822B1/pl unknown
- 2002-04-26 WO PCT/JP2002/004279 patent/WO2002088110A1/ja not_active Ceased
- 2002-04-26 CN CNB028126246A patent/CN1273466C/zh not_active Expired - Lifetime
- 2002-04-26 TW TW091108719A patent/TWI324154B/zh not_active IP Right Cessation
2003
- 2003-10-08 ZA ZA200307861A patent/ZA200307861B/en unknown
- 2003-10-14 NO NO20034595A patent/NO326325B1/no not_active IP Right Cessation
2004
- 2004-06-07 US US10/861,446 patent/US7211587B2/en not_active Expired - Fee Related
2009
- 2009-10-21 JP JP2009242477A patent/JP2010077131A/ja not_active Withdrawn
2018
- 2018-01-31 NL NL300927C patent/NL300927I9/nl unknown
- 2018-02-05 NO NO2018005C patent/NO2018005I1/no unknown
- 2018-02-06 FR FR18C1006C patent/FR18C1006I2/fr active Active
- 2018-02-08 BE BE2018C008C patent/BE2018C008I2/nl unknown

Also Published As

Publication number	Publication date
US20040229876A1 (en)	2004-11-18
EP1652847A1 (en)	2006-05-03
NL300927I9 (nl)	2019-02-05
RU2283841C2 (ru)	2006-09-20
BRPI0209216B8 (pt)	2021-05-25
NO20034595L (no)	2003-12-19
EP1652847A3 (en)	2006-08-02
RU2003134376A (ru)	2005-04-20
EP1382604A1 (en)	2004-01-21
BRPI0209216B1 (pt)	2017-05-30
CN1273466C (zh)	2006-09-06
PL209822B1 (pl)	2011-10-31
BE2018C008I2 (es)	2021-02-04
EP1382604A4 (en)	2004-09-08
AU2002255284B2 (en)	2007-10-04
FR18C1006I1 (fr)	2018-03-16
KR20040015143A (ko)	2004-02-18
TWI324154B (es)	2010-05-01
DE60208364T2 (de)	2006-09-28
US7211587B2 (en)	2007-05-01
DE60208364D1 (de)	2006-02-02
CN1543459A (zh)	2004-11-03
ATE396988T1 (de)	2008-06-15
KR100879669B1 (ko)	2009-01-21
EP1652847B1 (en)	2008-05-28
ZA200307861B (en)	2004-10-08
CA2445333A1 (en)	2002-11-07
US20030087907A1 (en)	2003-05-08
US6821987B2 (en)	2004-11-23
FR18C1006I2 (fr)	2019-03-01
NZ529046A (en)	2005-10-28
PL367105A1 (en)	2005-02-21
IL158459A0 (en)	2004-05-12
ES2256466T3 (es)	2006-07-16
NL300927I1 (nl)	2018-12-04
HK1070649A1 (en)	2005-06-24
CA2445333C (en)	2011-03-22
EP1382604B1 (en)	2005-12-28
DE60226912D1 (de)	2008-07-10
WO2002088110A1 (en)	2002-11-07
BR0209216A (pt)	2004-07-06
NO20034595D0 (no)	2003-10-14
JP2010077131A (ja)	2010-04-08
MXPA03009662A (es)	2004-12-06
NO2018005I1 (no)	2018-02-05
NO326325B1 (no)	2008-11-10

Publication	Publication Date	Title
DK1382604T3 (da)	2006-04-18	Quinolinderivater med en azolylgruppe og quinazolinderivater
NO20012617D0 (no)	2001-05-29	Kinolin- og kinzolinderivater
DE69418704D1 (de)	1999-07-01	Anthranilsäure derivate
AP1753A (en)	2007-07-18	Thiophene derivatives as antiviral agents for flavvivirus infection
ATE302775T1 (de)	2005-09-15	Carbolinderivate
EA200300982A1 (ru)	2004-12-30	Гетероциклические производные для лечения рака и других пролиферативных заболеваний
ATE346067T1 (de)	2006-12-15	Carbolinderivate
DK0918776T3 (da)	2004-07-12	Totalsyntese af antitumor acylfulvener
DK0784055T3 (da)	2003-06-02	Pyrimidinylpyrazolderivater
NO20025053L (no)	2002-11-29	Benzo[b]tiofen-derivat og fremgangsmÕte for fremstilling derav
FI952420A0 (fi)	1995-05-18	Glukopyranosidibentsotiofeenit
ATE245147T1 (de)	2003-08-15	Substituierte aminochinazolinon (thion) derivate
ATE275133T1 (de)	2004-09-15	1,2-dihydro-2-oxochinolin-derivate
ATE420855T1 (de)	2009-01-15	2-substituierte vitamin-d-derivate
ATE268769T1 (de)	2004-06-15	Pyrimidinderivate mit antitumor-wirkung